By AusCann Group Holdings Ltd on Thursday, 06 September 2018
Category: Vertically Integrated

Auscann targeting pain management with Australian cannabinoid products

viewAusCann Group Holdings Ltd

Elaine Darby, managing director of Auscann Group Holdings Ltd (), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney.

Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019. The company has established several strategic partnerships in Australia, Chile and Canada and is advancing its position as a fully-integrated cannabinoid pharmaceutical company.

ASX:AC8

Market: ASX
Market Cap: $93.53 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

Full interview: Ideanomics wins more than $7M in financing to build out its...

Ideanomics (NASDAQ: IDEX) CEO Alf Poor tells Proactive the FinTech company 's subsidiary, with projects in the electric vehicle market, has received an initial investment of $7.2 million from Qingdao Xingyang City Investment Co., Ltd. The company will headquarter its MEG subsidiary in...

11 hours, 5 minutes ago

2 min read

Related Posts